Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID TURBAY

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1922082411
CMS profile
132729
Location
EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$26,830.03

154 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID TURBAY

NPI 1922082411 · CMS profile ID 132729

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922082411?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID TURBAY, NPI 1922082411, CMS profile ID 132729. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922082411?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DAVID TURBAY, NPI 1922082411, CMS profile ID 132729. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922082411?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DAVID TURBAY, NPI 1922082411, CMS profile ID 132729, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 154 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1922082411?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

154 matching records · $26,830.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 154 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 154.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Abbott Laboratories $28.3304/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815475223 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.5204/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763696430 CMS
Novartis Pharmaceuticals Corporation $7.2804/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326803 CMS
PFIZER INC. $19.0104/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832657663 CMS
AstraZeneca Pharmaceuticals LP $100.0004/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834339135 CMS
AstraZeneca Pharmaceuticals LP $15.3204/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834345403 CMS
AstraZeneca Pharmaceuticals LP $21.5004/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834330677 CMS
Abbott Laboratories $115.3904/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815462703 CMS
Novartis Pharmaceuticals Corporation $7.1404/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326795 CMS
Novartis Pharmaceuticals Corporation $5.7104/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326799 CMS
Esperion Therapeutics, Inc. $15.8704/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838426317 CMS
Novartis Pharmaceuticals Corporation $8.1104/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326791 CMS
E.R. Squibb & Sons, L.L.C. $28.7204/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783591627 CMS
Abbott Laboratories $93.9103/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818456565 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $2.1103/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763696432 CMS
Novartis Pharmaceuticals Corporation $5.3003/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326787 CMS
ABIOMED $19.1103/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848773617 CMS
Amgen Inc. $13.3203/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825264347 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $750.0003/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763696440 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $6.0503/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763696434 CMS
Abbott Laboratories $15.4203/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818439423 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $750.0003/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763696442 CMS
E.R. Squibb & Sons, L.L.C. $10.1703/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783591619 CMS
AstraZeneca Pharmaceuticals LP $100.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834324649 CMS
AstraZeneca Pharmaceuticals LP $100.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834339083 CMS
PFIZER INC. $17.7703/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832722099 CMS
Novartis Pharmaceuticals Corporation $6.4803/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326783 CMS
Merck Sharp & Dohme Corporation $18.8503/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848332991 CMS
E.R. Squibb & Sons, L.L.C. $19.3002/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783591615 CMS
Actelion Pharmaceuticals US, Inc. $19.1802/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788824529 CMS
Novartis Pharmaceuticals Corporation $7.3702/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326775 CMS
Novartis Pharmaceuticals Corporation $4.8602/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326779 CMS
Esperion Therapeutics, Inc. $21.0402/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838426311 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.9702/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763696436 CMS
E.R. Squibb & Sons, L.L.C. $19.8502/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783591611 CMS
Novartis Pharmaceuticals Corporation $4.3302/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326763 CMS
Novartis Pharmaceuticals Corporation $7.8202/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326771 CMS
AstraZeneca Pharmaceuticals LP $1,850.0002/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834345381 CMS
Actelion Pharmaceuticals US, Inc. $26.3902/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788824531 CMS
AstraZeneca Pharmaceuticals LP $1,850.0002/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834326531 CMS
Novartis Pharmaceuticals Corporation $7.6702/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326767 CMS
PFIZER INC. $19.7701/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832685439 CMS
Abbott Laboratories $32.8101/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818404789 CMS
Abbott Laboratories $70.8901/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818404791 CMS
Novartis Pharmaceuticals Corporation $7.8701/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326759 CMS
E.R. Squibb & Sons, L.L.C. $22.9301/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783591603 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.9201/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763696438 CMS
Novartis Pharmaceuticals Corporation $7.4801/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326755 CMS
AstraZeneca Pharmaceuticals LP $19.3501/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834337599 CMS
Novartis Pharmaceuticals Corporation $7.7001/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813326751 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,313.68 251
PY2020 $32,279.87 147
PY2021 $26,830.03 154
PY2022 $19,309.98 161
PY2023 $18,414.36 179
PY2024 $35,671.41 209
PY2025 $16,917.99 158

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,255.68 6
PY2025 Principal investigator $782,981.43 20
PY2024 Recipient $45,690.96 2
PY2024 Principal investigator $348,978.33 7
PY2023 Recipient $14,566.16 1
PY2023 Principal investigator $268,122.92 6
PY2022 Principal investigator $101,130.75 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $23,702.05 11/05/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH, INC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185546568
Recipient Amgen Inc. $496.39 09/09/2025 Covered Recipient Physician A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246637278
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,467.20 08/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190309408
Principal investigator 1 Amgen Inc. $20,860.47 08/06/2025 Non-covered Recipient Entity
DAVID TURBAY, MD, PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246640649
Recipient Amgen Inc. $261.00 07/31/2025 Covered Recipient Physician A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246637276
Recipient Amgen Inc. $435.00 07/31/2025 Covered Recipient Physician A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) No dispute reported 06/30/2026 1246637282
Principal investigator 1 Amgen Inc. $8,701.58 07/24/2025 Non-covered Recipient Entity
DAVID TURBAY, MD, PLLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246640647
Principal investigator 1 Novartis Pharmaceuticals Corporation $454.28 07/15/2025 Non-covered Recipient Entity
DAVID TURBAY MD PLLC
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190312201
Recipient Amgen Inc. $145.00 06/30/2025 Covered Recipient Physician MARITIME-CV Ph3 ASCVD Outcomes Trial No dispute reported 06/30/2026 1246637284
Principal investigator 1 Amgen Inc. $99,433.50 06/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246641115
Principal investigator 1 Amgen Inc. $106,545.00 06/26/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246641141
Recipient Amgen Inc. $270.00 06/23/2025 Covered Recipient Physician A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) No dispute reported 06/30/2026 1246637280
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,488.00 06/23/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH, INC
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185546561
Principal investigator 1 AstraZeneca Pharmaceuticals LP $87,427.60 05/09/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH, INC
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185546563
Principal investigator 1 Amgen Inc. $12,662.10 04/24/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246641101
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,883.65 03/31/2025 Non-covered Recipient Entity
DAVID TURBAY, MD, PLLC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190308398
Principal investigator 1 AstraZeneca Pharmaceuticals LP $91,491.40 03/14/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH, INC
A Phase III Randomised Doubleblind Study to Evaluate the Effect of Balcinrenone Dapagliflozin Compared with Dapagliflozin on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function No dispute reported 06/30/2026 1185546565
Recipient Amgen Inc. $3,648.29 02/22/2025 Covered Recipient Physician A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) No dispute reported 06/30/2026 1246637274
Principal investigator 1 AstraZeneca UK Limited $107,860.90 02/07/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH, INC
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185546571
Principal investigator 1 Amgen Inc. $2,598.24 02/06/2025 Non-covered Recipient Entity
DAVID TURBAY, MD, PLLC
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246640645
Principal investigator 1 Novartis Pharmaceuticals Corporation $30,320.50 02/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190310216
Principal investigator 1 Novartis Pharmaceuticals Corporation $54,955.00 02/04/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190310222
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,330.55 01/30/2025 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190310210
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,569.29 01/24/2025 Non-covered Recipient Entity
DAVID TURBAY MD PLLC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190312199
Principal investigator 1 Novartis Pharmaceuticals Corporation $55,797.08 01/20/2025 Non-covered Recipient Entity
DAVID TURBAY MD PLLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190312197
Principal investigator 1 Amgen Inc. $433.04 01/15/2025 Non-covered Recipient Entity
DAVID TURBAY, MD
OCEAN(a)-Outcomes Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction Outcomes trial No dispute reported 06/30/2026 1246640651